Everforth Inc annual report, FY2015

Filing summary: On Assignment, Inc. (NYSE: ASGN), fiscal year ended December 31, 2015

Entity and period: The supplied filing is On Assignment, Inc.’s 2015 Form 10-K, not a filing identified as Everforth Inc. It reports full-year results; fourth-quarter figures are also included below where available. Unless stated otherwise, dollar amounts are in millions.

Business context and reporting period

On Assignment provided contract, contract-to-hire, and permanent-placement staffing in technology, life sciences, and creative markets through its Apex and Oxford segments. Apex represented 72% of 2015 revenue and Oxford 28%. Approximately 96% of revenue came from U.S. operations; no single client exceeded 5% of revenue.

The year included the June 2015 acquisition of Creative Circle and the April 2015 acquisition of LabResource. The Physician segment was sold in February 2015; its results are reported as discontinued operations. The company’s strategic goal was to reach $3.0 billion in revenue by 2018 while maintaining attractive margins and EPS growth.

Key financial metrics

MetricFY 2015FY 2014Change / context
Revenue$2,065.0$1,724.7Up 19.7% reported; up 11.1% pro forma, or 12.0% at constant currency
Gross profit / margin$678.7 / 32.9%$557.4 / 32.3%Gross profit up 21.8%; reported margin up 0.6 percentage points. Pro forma margin was 33.4%, down about 0.1 point
Operating income$152.1$137.8Up 10.4%; operating margin was about 7.4%, versus 8.0%
Income from continuing operations$71.4$73.5Down 2.8%
Net income$97.7$77.2Includes a $25.7 after-tax gain on the Physician sale
Diluted EPS$1.84$1.42Continuing-operations diluted EPS was $1.35 versus $1.35
Operating cash flow$117.5$96.0Increase of $21.5
Cash and working capital at year-end$23.9 / $253.9$28.9 / $201.3$6.1 of 2015 cash was held abroad; company said it did not intend to repatriate it
Debt at year-end$774.0 gross; $755.5 net carrying value$415.1 grossNew credit facility funded refinancing and acquisition; $96.5 available on revolver

FY 2015 investing cash outflow was $461.5, including $552.8 for acquisitions, partly offset by $115.4 net proceeds from the Physician sale. Financing cash inflow was $337.7. Capital expenditures were $24.7. The company reported a 3.02x funded-debt-to-EBITDA ratio against a 4.50x maximum at December 31, 2015, and compliance with its debt covenants.

Fourth quarter: Revenue was $577.5 versus $441.0 in Q4 2014; gross profit was $192.9 versus $142.5. Income from continuing operations was $19.2 versus $19.5, and net income was $19.3 versus $20.5.

Material changes versus prior comparable period

  • Reported revenue growth included $174.9 from the 2015 acquisitions; management reported 9.6% organic growth, or 10.5% at constant currency. Pro forma revenue growth was 11.1%.
  • Apex revenue rose 25.0% reported and 12.9% pro forma. Its pro forma growth accelerated from 8.6% in Q1 to 17.4% in Q4. Oxford revenue rose 8.1% reported and 6.6% pro forma.
  • Permanent-placement revenue increased to $118.0 from $83.0 and reached 5.7% of total revenue, compared with 4.8% in 2014.
  • SG&A increased to $492.2 from $397.5 and rose to 23.8% of revenue from 23.0%. The filing attributes the increase to acquired operations, higher headcount, and $14.9 of acquisition, integration, and strategic-planning costs.
  • Interest expense rose to $26.4 from $12.7, primarily due to higher debt and a higher effective rate (4.2% versus 3.3%). A $3.8 loan-cost write-off related to the June refinancing was also recorded.
  • Reported net income benefited from the Physician-sale gain; continuing-operations income declined despite revenue growth.

Outlook, commentary, risks, and unusual items

  • Outlook: Management’s stated strategic target was $3.0 billion in revenue by 2018, supported by organic growth and disciplined acquisitions. The filing does not provide formal 2016 financial guidance. It cites industry forecasts for 2016 growth in U.S. professional temporary staffing markets, including IT and marketing/creative, but these are external industry estimates, not company guidance.
  • Debt and rates: The $975 million credit facility has variable-rate borrowings and restrictive covenants. Management estimated that a 100-basis-point rate change would affect annual interest expense by approximately $7.7 million at year-end debt levels. The company expected operating cash flow, working capital, and credit availability to fund obligations and needs for the next 12 months.
  • Operating risks: Demand is cyclical and sensitive to economic activity, client project spending, and employment trends. Other disclosed risks include competition and pricing pressure, recruiting and retaining qualified professionals, worker-classification and employment regulation, litigation, information-system and cybersecurity events, and acquisition integration.
  • Acquisition and valuation items: Creative Circle’s purchase price included $540.0 cash, $30.2 in stock, and estimated contingent consideration. Goodwill was $874.9 at year-end; management reported no 2015 impairment but noted sensitivity to forecasts and valuation assumptions. Contingent consideration was estimated at $21.0 at year-end.
  • Contingencies: The company reported ordinary-course legal matters that it did not expect to have a material financial effect, and ongoing indemnification obligations from divested businesses. Workers’ compensation reserves were $15.0 gross, with anticipated insurance and indemnification recoveries of $13.2. No significant off-balance-sheet arrangements were reported beyond operating leases and standby letters of credit.
  • Controls and audit: The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Management and the auditor excluded Creative Circle from the 2015 internal-control assessment; it represented 33.2% of total assets and 18.8% of income before taxes.

Most important facts for investors to verify

  • Confirm the registrant identity: this filing is for On Assignment, Inc., not Everforth Inc.
  • Assess underlying growth and earnings excluding acquisitions and the $25.7 after-tax Physician-sale gain; compare reported and pro forma results.
  • Track debt paydown, variable-rate exposure, covenant headroom, and the effect of acquisition financing on interest expense and cash flow.
  • Review Creative Circle integration, subsequent organic growth, margin performance, and the substantial goodwill and intangible-asset balances.
  • Consider the 2015 internal-control assessment’s exclusion of Creative Circle and monitor completion of integration into company controls.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.